Scarica l'app Stockscreener
26.23
4.18%
-1.145
Dopo l'orario di chiusura:
26.39
0.16
+0.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Precedente Chiudi:
$27.38
Aprire:
$27.22
Volume 24 ore:
1.01M
Relative Volume:
0.76
Capitalizzazione di mercato:
$2.84B
Reddito:
$577.74M
Utile/perdita netta:
$-149.78M
Rapporto P/E:
-18.74
EPS:
-1.4
Flusso di cassa netto:
$-78.21M
1 W Prestazione:
-9.58%
1M Prestazione:
-21.49%
6M Prestazione:
+45.88%
1 anno Prestazione:
+95.89%
Intervallo 1D:
$26.15
$27.59
Intervallo di 1 settimana:
$26.15
$29.29
Portata 52W:
$11.70
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Nome
Novocure Ltd
Settore
Industria
Telefono
44 (0)15 3475 6700
Indirizzo
NO. 4 THE FORUM, ST. HELIER
Confronta NVCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
26.23 | 2.84B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
113.02 | 196.03B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.65 | 140.97B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
362.80 | 138.31B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
85.25 | 109.31B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
71.04 | 41.90B | 6.60B | 4.16B | 490.10M | 6.93 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Iniziato | SVB Securities | Outperform |
| 2023-07-31 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2023-05-16 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Reiterato | H.C. Wainwright | Buy |
| 2022-11-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Downgrade | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-08 | Iniziato | Loop Capital | Buy |
| 2022-02-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2022-01-03 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-14 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-01-25 | Reiterato | Piper Sandler | Overweight |
| 2020-09-23 | Iniziato | Northland Capital | Outperform |
| 2020-09-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Downgrade | Truist | Buy → Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Perform |
| 2020-05-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Aggiornamento | SunTrust | Hold → Buy |
| 2019-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2018-11-02 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Iniziato | Evercore ISI | Outperform |
| 2018-04-18 | Reiterato | Mizuho | Buy |
| 2018-02-23 | Reiterato | Mizuho | Buy |
| 2017-05-24 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Reiterato | Wedbush | Outperform |
| 2016-01-19 | Iniziato | Barclays | Underweight |
| 2015-12-02 | Iniziato | Deutsche Bank | Hold |
Mostra tutto
Novocure Ltd Borsa (NVCR) Ultime notizie
NovoCure Ltd (NVCR) Shares Down 3.67% on Jan 14 - GuruFocus.com
NovoCure (NASDAQ:NVCR) Earns "Buy" Rating from HC Wainwright - MarketBeat
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings) - Benzinga
NovoCure’s (NVCR) Neutral Rating Reaffirmed at Wedbush - Defense World
NovoCure's (NVCR) Neutral Rating Reiterated at Wedbush - MarketBeat
Is Now The Time To Buy NovoCure Ltd (NASDAQ: NVCR) Stock? - Stocks Register
Novocure reports revenue growth, FDA approvals in 2024 - Investing.com India
Novocure Reports Strong 19% Revenue Growth, Hits $605M as Cancer Treatment Platform Expands - StockTitan
Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 97% gain - Simply Wall St
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Versant Capital Management Inc - Defense World
NovoCure Limited (NASDAQ:NVCR) Receives $32.67 Average PT from Brokerages - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Novocure CEO to Present at J.P. Morgan Healthcare Conference, Announces Investor Meetings - StockTitan
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Franklin Resources Inc. - MarketBeat
Geode Capital Management LLC Acquires 29,871 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure (NASDAQ:NVCR) Reaches New 12-Month HighShould You Buy? - MarketBeat
Research Analysts’ Recent Ratings Updates for NovoCure (NVCR) - Defense World
Tumor Treating Fields Market Growth in Future Scope 2024-2031 | Novocure GmbH and Zai Lab - openPR
Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges By Investing.com - Investing.com South Africa
Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges - Investing.com
NovoCure (NASDAQ:NVCR) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Novocure Stock Hits 52-Week High at $32.65 Amidst Strong Yearly Growth - Investing.com Australia
NovoCure (NASDAQ:NVCR) Shares Gap Up on Analyst Upgrade - MarketBeat
Novocure price target raised to $42 from $28 at Piper Sandler - Yahoo Finance
Novocure Stock Hits 52-Week High at $32.65 Amidst Strong Yearly Growth By Investing.com - Investing.com South Africa
NovoCure (NASDAQ:NVCR) Price Target Raised to $42.00 - MarketBeat
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. - MSN
Brokerages Set NovoCure Limited (NASDAQ:NVCR) Target Price at $30.33 - MarketBeat
Quantinno Capital Management LP Cuts Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
47,034 Shares in NovoCure Limited (NASDAQ:NVCR) Bought by Weiss Asset Management LP - MarketBeat
NovoCure (NASDAQ:NVCR) Shares Gap UpHere's Why - MarketBeat
Holocene Advisors LP Purchases 22,276 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
MetLife Investment Management LLC Has $963,000 Holdings in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Why NovoCure Stock Was Winning Big This Week - Mitrade
BNP Paribas Financial Markets Has $2.75 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? - sharewise
CORRECTING and REPLACING – Novocure to Report Third Quarter 2016 Financial Results - Marketscreener.com
Edgestream Partners L.P. Takes Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Intech Investment Management LLC Makes New Investment in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure Target of Unusually Large Options Trading (NASDAQ:NVCR) - Defense World
Novocure Stock Earns 96 RS Rating - Yahoo! Voices
NovoCure stock target increased on positive trial results By Investing.com - Investing.com Nigeria
NovoCure stock target increased on positive trial results - Investing.com
Novocure reports positive phase 3 results for tumor treating fields therapy - OutSourcing-Pharma.com
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals - Yahoo Finance
Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump - Simply Wall St
Novocure stock hits 52-week high at $28.26 amid robust growth - Investing.com Canada
Bridgewater Associates LP Sells 41,898 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Novocure Ltd Azioni (NVCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.10%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):